Compare AR & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AR | RDY |
|---|---|---|
| Founded | 2002 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8B | 9.9B |
| IPO Year | 2013 | 2001 |
| Metric | AR | RDY |
|---|---|---|
| Price | $37.51 | $12.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 1 |
| Target Price | ★ $47.13 | $16.90 |
| AVG Volume (30 Days) | ★ 4.6M | 2.8M |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | N/A | ★ 0.52% |
| EPS Growth | ★ 1027.78 | N/A |
| EPS | ★ 2.62 | N/A |
| Revenue | ★ $5,275,823,000.00 | N/A |
| Revenue This Year | $29.74 | $7.72 |
| Revenue Next Year | $5.07 | $3.50 |
| P/E Ratio | ★ $14.44 | $18.67 |
| Revenue Growth | ★ 21.97 | N/A |
| 52 Week Low | $29.10 | $11.36 |
| 52 Week High | $45.75 | $15.67 |
| Indicator | AR | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 63.88 | 47.02 |
| Support Level | $32.82 | $12.19 |
| Resistance Level | $39.63 | $13.95 |
| Average True Range (ATR) | 1.06 | 0.20 |
| MACD | 0.34 | 0.11 |
| Stochastic Oscillator | 98.24 | 77.50 |
Antero Resources is an exploration and production firm whose operations represent a pure play in the Marcellus Shale, located in northern West Virginia. The company started in 2002 as an E&P focused on the Barnett Shale (Fort Worth, Texas). Antero redefined itself in Appalachia's Marcellus Shale in 2005. In 2012, shortly before Antero's 2013 IPO, Antero Midstream Partners was formed to handle the company's rapidly growing gas volumes. In 2026, the firm narrowed its focus further by selling its Ohio Utica assets and using the proceeds to acquire additional Marcellus acreage from HG Energy. Just over half of its production and earning power is tied to natural gas, with the remainder mostly NGLs, where it holds a leading position, and some crude oil.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.